Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
budesonide (Ferring Pharmaceuticals)
- Development stage
- Approved
- Lead developer
- Cosmo Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Budesonide (Cortiment) is a synthetic glucocorticoid with high local anti-inflammatory activity and low systemic bioavailability due to extensive first-pass metabolism in the liver. Developed by Cosmo Pharmaceuticals and licensed to Ferring Pharmaceuticals, Cortiment is specifically designed for the induction of remission in patients with mild-to-moderate active ulcerative colitis. The drug employs the Multi-Matrix System (MMX) technology, which consists of a multi-layered tablet structure that delays release until it reaches the terminal ileum and then ensures a slow, uniform distribution of budesonide throughout the entire length of the colon. This targeted delivery mechanism allows for effective treatment of colonic inflammation while significantly reducing the risk of systemic corticosteroid-related side effects compared to conventional steroids like prednisolone.
- Brand names
- CortimentUceris
- Other names
- budesonide MMXbudesonide multi-matrix system
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on budesonide (Ferring Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on budesonide (Ferring Pharmaceuticals).